We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eureka Genomics Lands a DHS Phase II Award
News

Eureka Genomics Lands a DHS Phase II Award

Eureka Genomics Lands a DHS Phase II Award
News

Eureka Genomics Lands a DHS Phase II Award

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eureka Genomics Lands a DHS Phase II Award"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

After successfully completing a DHS Phase I contract, Eureka Genomics has been awarded a $750,000 Phase II SBIR from The Department of Homeland Security (DHS) Science and Technology (S&T), to be completed by June 2013. According to Dr. Viacheslav Fofanov, Director of Bioinformatics for Eureka Genomics, “The ability to detect the presence of rare variants (either known or previously uncharacterized) in cell populations (viral, bacterial, and eukaryotic) could lead to significant improvements in the ability to fingerprint a sample and, as a consequence, provide vital information for the investigation and prosecution of bioterrorism attacks or attempts. In addition to forensic applications, the ability to detect rare or minority variants in bacterial and viral populations can significantly contribute to understanding of the complex host-pathogen interaction process and lead to new ways to diagnose and treat infections caused by microorganisms such as HIV, HCV, and Mycobacterium tuberculosis and cancers where there are multiple choice of therapeutics.”

The development of novel methods for the detection of microorganisms is part of Eureka Genomics main research and business focus. The Company is currently working on the identification of microorganisms associated with colorectal cancer, in collaboration with Baylor Research Institute, and the identification of microorganisms associated with preterm birth.

Advertisement